These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27650607)

  • 1. The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice.
    Viarisio D; Müller-Decker K; Hassel JC; Alvarez JC; Flechtenmacher C; Pawlita M; Gissmann L; Tommasino M
    J Invest Dermatol; 2017 Jan; 137(1):261-264. PubMed ID: 27650607
    [No Abstract]   [Full Text] [Related]  

  • 2. The natural history of malignancies under conditions of BRAF inhibitor stimulation.
    White RM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):135-6. PubMed ID: 21117980
    [No Abstract]   [Full Text] [Related]  

  • 3. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
    Sibaud V; Chevreau C
    Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
    [No Abstract]   [Full Text] [Related]  

  • 4. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
    Viros A; Hayward R; Martin M; Yashar S; Yu CC; Sanchez-Laorden B; Zambon A; Niculescu-Duvaz D; Springer C; Lo RS; Marais R
    J Invest Dermatol; 2013 Jan; 133(1):274-6. PubMed ID: 22895366
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of metastatic melanoma with BRAF inhibitors].
    Hafner C
    Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
    [No Abstract]   [Full Text] [Related]  

  • 6. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
    Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
    [No Abstract]   [Full Text] [Related]  

  • 7. E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice.
    Viarisio D; Mueller-Decker K; Kloz U; Aengeneyndt B; Kopp-Schneider A; Gröne HJ; Gheit T; Flechtenmacher C; Gissmann L; Tommasino M
    PLoS Pathog; 2011 Jul; 7(7):e1002125. PubMed ID: 21779166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
    Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
    J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
    Vigarios E; Lamant L; Delord JP; Fricain JC; Chevreau C; Barrés B; Gomez-Roca C; Boulanger M; Sibaud V
    Br J Dermatol; 2015 Jun; 172(6):1680-1682. PubMed ID: 25495246
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.
    Cammareri P; Rose AM; Vincent DF; Wang J; Nagano A; Libertini S; Ridgway RA; Athineos D; Coates PJ; McHugh A; Pourreyron C; Dayal JH; Larsson J; Weidlich S; Spender LC; Sapkota GP; Purdie KJ; Proby CM; Harwood CA; Leigh IM; Clevers H; Barker N; Karlsson S; Pritchard C; Marais R; Chelala C; South AP; Sansom OJ; Inman GJ
    Nat Commun; 2016 Aug; 7():12493. PubMed ID: 27558455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BRAF mutation detection in metastatic melanoma].
    Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
    Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
    [No Abstract]   [Full Text] [Related]  

  • 15. Vemurafenib and cutaneous adverse events--report of five cases.
    Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
    An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
    Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations.
    Schrama D; Groesser L; Ugurel S; Hafner C; Pastrana DV; Buck CB; Cerroni L; Theiler A; Becker JC
    JAMA Dermatol; 2014 Nov; 150(11):1180-6. PubMed ID: 24943872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
    Cassius C; Pages C; Roux J; Lhote R; Lavocat R; Réa D; Bagot M; Mourah S; Battistella M; Lebbé C; Dumaz N
    J Invest Dermatol; 2016 Jun; 136(6):1302-1305. PubMed ID: 26854489
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.